Filing Details

Accession Number:
0000950170-24-024970
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-04 17:25:40
Reporting Period:
2024-03-01
Accepted Time:
2024-03-04 17:25:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1029142 Dynavax Technologies Corp DVAX Pharmaceutical Preparations (2834) 330728374
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1812025 Justin Burgess C/O Dynavax Technologies
2100 Powell Street, Suite 720
Emeryville CA 94608
Chief Accounting Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-01 4,334 $11.12 17,759 No 4 M Direct
Common Stock Acquisiton 2024-03-01 2,767 $9.41 20,526 No 4 M Direct
Common Stock Disposition 2024-03-01 7,101 $12.78 13,425 No 4 S Direct
Common Stock Disposition 2024-03-01 13,425 $12.78 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2024-03-01 4,334 $0.00 0 $11.12
Common Stock StockOptions (Right to Buy) Disposition 2024-03-01 2,767 $0.00 0 $9.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
8,666 2030-02-15 No 4 M Direct
0 2028-02-02 No 4 M Direct
Footnotes
  1. Code M - Exercise or conversion of derivative security
  2. Code S - Open market or private sale of non-derivative or derivative security
  3. This transaction was executed in multiple trades at prices ranging from $12.73 to $12.81; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
  4. This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
  5. This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.